1. Home
  2. PMAX vs LTRN Comparison

PMAX vs LTRN Comparison

Compare PMAX & LTRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Powell Max Limited

PMAX

Powell Max Limited

HOLD

Current Price

$3.37

Market Cap

8.2M

Sector

N/A

ML Signal

HOLD

Logo Lantern Pharma Inc.

LTRN

Lantern Pharma Inc.

HOLD

Current Price

$2.47

Market Cap

22.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PMAX
LTRN
Founded
2019
2013
Country
Hong Kong
United States
Employees
53
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.2M
22.2M
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
PMAX
LTRN
Price
$3.37
$2.47
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.5M
213.5K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
18.65
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.20
$1.11
52 Week High
$5.20
$5.74

Technical Indicators

Market Signals
Indicator
PMAX
LTRN
Relative Strength Index (RSI) 61.78 57.79
Support Level $1.90 $1.96
Resistance Level $5.01 $3.67
Average True Range (ATR) 0.62 0.25
MACD 0.05 0.00
Stochastic Oscillator 50.49 73.39

Price Performance

Historical Comparison
PMAX
LTRN

About PMAX Powell Max Limited

Powell Max Ltd is an financial communications services provider. Its financial communications services cover a full range of financial printing, corporate reporting, communications and language support services from inception to completion, including typesetting, proofreading, translation, design, printing, electronic reporting, newspaper placement and distribution. It operates in a single business segment which is the provision of corporate financial communications and financial printing services. All operations are carried in Hong Kong.

About LTRN Lantern Pharma Inc.

Lantern Pharma Inc is a biopharmaceutical company focused on developing oncology drug candidates using its artificial intelligence platform. The company utilizes its proprietary RADR platform to identify, develop, and advance small molecule therapies and antibody-drug conjugates, with a pipeline that includes three lead small molecule drug candidates (LP-300, LP-184, and LP-284) targeting solid tumors and blood cancers. It also advances programs through its subsidiary focused on central nervous system and brain cancers.

Share on Social Networks: